The power in tailored therapeutics is for us to say more clearly to payers, providers, and patients—this drug is not for everyone, but it is for you—that is exceedingly powerful.

—JOHN C. LECHLEITER, PRESIDENT AND CEO, ELI LILLY AND COMPANY
PERSONALIZED MEDICINE OFFERS A VISION of health care in the 21st century that incorporates new discoveries in biology and the development of new molecular diagnostic tools that can guide therapeutic decisions and move us away from a one-size-fits-all trial and error paradigm into one that is more precise and targeted to groups of patients most likely to benefit.

By increasing efficacy, decreasing side effects including adverse events, and lowering systemic costs, even if the cost of individual products may increase, personalized medicine tailors new medical treatments to patients based on their personal profiles, if not personal values as well. It also represents a paradigm shift in the way we think about medicine.
Personalized medicine, according to the President’s Council of Advisors on Science and Technology, refers to the tailoring of medical treatment to the individual characteristics of each patient in order to classify individuals into subpopulations that differ in their susceptibility to a particular disease or their response to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not.

PERSONALIZED MEDICINE

Paradigm shifts, especially in medicine, do not happen just because the science or new technologies suggest they should. Based on that assumption, at the end of 2004, the Personalized Medicine Coalition (PMC) was launched by some 20 institutions, which spanned the health care ecosystem. They included the pharmaceutical, biotechnology, and diagnostic industries, tool manufacturers, academic health centers, venture capitalists, insurance companies, and patient advocates. Representing innovators, scientists, providers, payers, and patients, PMC became an international educational and advocacy organization, now numbering over 225 institutions. Along with raising personalized medicine’s profile, the Coalition’s mission is to advocate for changes that will increase investment in personalized medicine and facilitate its adoption so that both patients and the health system will benefit from improved clinical care and increased overall value.
AT THIS TIME OF UNPRECEDENTED scientific breakthroughs and technological advancements, personalized health care has the capacity to:

• Diagnose a large number of devastating human diseases more accurately.
• Predict individual susceptibility to disease, based on genetic and other factors.
• Detect the onset of disease at the very earliest stages.
• Preempt the progression of disease.
• Target medicines and dosages more precisely and safely to each patient.
• Increase the efficiency of the health care system by improving quality, accessibility, and affordability.

PMC’s third edition of its signature publication, _The Case for Personalized Medicine_, issued at the end of 2011, explained how patients with many different kinds of cancers, for example, are now offered routine molecular diagnoses to improve their chances of survival. Melanoma is no longer just melanoma; it can be characterized by whether it is BRAF positive or negative. Similarly, non-small cell lung cancer can be, for example, EGFR positive or ALK positive, and treated with a drug most likely to improve the patient’s health. In fact, scientists are beginning to appreciate the heterogeneity of most diseases, and drug companies are responding by developing more therapeutics for specific subpopulations as well as the processes that lead to drug resistance.

_The Case for Personalized Medicine_ points out that the number of commercially available personalized medicine products has increased from 13 in 2006, when the first edition of the document was published, to over 72 today.
MOVEMENT FROM A ONE-SIZE-FITS-ALL, trial and error world to one in which
the right patient gets the right treatment at the right time requires overcoming
numerous hurdles after the complexities of the science of human biology have been
determined. While the benefits of personalized health care are clear—knowing what
works, knowing why it works, knowing whom it works for, and applying that knowl-
edge to address patient needs—the intervening variables that determine the pace of
personalized medicine’s development and adoption are more complex. Decades-long
patterns of intertwined and/or misaligned regulations, guidelines, investment incentives,
and perceptions must be changed to accelerate the development of new personalized
medicine products for patients.

PMC believes that these hurdles are many, but three in particular focus our attention:
regulation, reimbursement, and education, in part because they are areas of contention.

REGULATION
While the hallmark of personalized medicine is its ability to link diagnostics and
drugs, different business models, different development timelines, and especially
different regulatory structures define the industries. Within FDA, different centers
governed by different rules, regulations, and cultures evaluate drugs and diagnostics.
For historic reasons, most molecular diagnostics products enter the market under
the authority granted by the Clinical Laboratory Improvement Act of 1988 to the
Centers for Medicare and Medicaid Services to oversee laboratories. Large reference
clinical laboratories, stand-alone “esoteric” labs which offer specific services, and
academic health centers, which develop and conduct many molecular tests, all operate

OVERCOMING CHALLENGES
in this system, a system that stimulates the development of a great many diagnostic tests, even if it is not one that encourages co-development of highly-regulated drugs with diagnostics.

FDA has recognized this challenge. Recently, it approved two new co-developed targeted therapeutics and diagnostics together in record time as well as other groundbreaking targeted therapeutics this year. It is expected to issue draft guidance documents to help clarify the field so that more are developed in the future. Congress is also considering a number of competing solutions to address questions regarding the regulation of laboratory developed tests (LDTs). PMC, believing that what is required is a clear and transparent regulatory system flexible enough to accommodate our rapidly growing understanding of individual variation believes that Congress should incentivize investment in co-developed products by enacting R&D tax credits, streamlining review, and ensuring Medicare coverage.

Meanwhile, as science and technology progress, the need to update our regulatory systems to accommodate these developments becomes more acute. The emergence of complex genetic testing, including whole genome sequencing, will further challenge a regulatory structure not designed to facilitate the development of personalized medicine, limiting access to new discoveries and treatments for serious diseases. Representing the patient point of view, PMC continues to engage the diagnostic, pharmaceutical, and payer communities in a dialog about how they can join forces to support the medicine of the future.

**COVERAGE, CODING AND PAYMENT**

Regulatory approval of personalized medicine products and services is necessary but not sufficient. Coverage and payment are also needed to encourage investment in new molecular diagnostics. While public and private insurers recognize the benefit of molecular testing in patient management,
payers rightly require evidence of its clinical, if not economic, value; though they have been slow to define what levels of evidence they consider adequate.

An open and critical issue is what kinds of evidence should determine coverage and payment decisions for products whose cost cannot justify a controlled randomized clinical trial or for changes like the introduction of new biomarkers that improve the product. Moreover, if diagnostic tests are not reimbursed, evidence of their utility cannot be developed, creating a classic “Catch 22” situation. Combined with CMS’s tendency to pay for innovative molecular tests based on materials and performance steps, rather than on their development costs (including clinical trials), complexity, or the difficulty in interpreting them, another hurdle has been added to the mix. In addition, with some notable exceptions, CMS rules for Medicare preclude payment for screening tests that predict and prevent disease before it occurs, a large part of the promise of personalized medicine.

To address these issues, and in concert with the payer community, PMC is focusing more attention on the evidentiary standards and data requirements for payer coverage and what incentives may be necessary to encourage development of personalized medicine diagnostic products. We will examine in particular the challenges that large scale randomized clinical trials pose for developing diagnostics, while also exploring alternative models for meeting evidentiary standards for multiple purposes.

**EDUCATION**

Physicians and other health care providers, it has been noted, sometimes are slow to change practice absent of conclusive evidence that the proposed change, notably one that requires a new procedure or test, will produce a better result. It is not enough that new products are brought to market. They must be adopted if patients are going to benefit.

A recent survey by the American Medical Association and a pharmacy benefit manager found that 98 percent of physicians are aware that patient genetic profiles influence therapy, but only 10 percent believe that they have the knowledge to use genetic information in practice. Combined with the inherent conservatism of many medical societies, that lack of understanding limits the pace of change and slows the improvement of clinical care. PMC believes that we need to build a personalized medicine informed health care workforce by educating providers at the front lines of clinical care about the power of personalized medicine, and will examine the best ways to incorporate personalized medicine concepts and products into the practice of medicine.
LOOKING FORWARD

As we wrote in The Case for Personalized Medicine, “The long arc of medical history has been one in which diagnostic capability has evolved from the metaphysical, to the anatomical, to the cellular, and ultimately to the molecular level. Now that a number of diseases can be sub-classified using evidence well beyond what is visibly obvious into categories that presage the course of disease and its likely response to treatment, there is an obligation to act on that information.”

We understand that the case is far from closed and that we need more evidence to support our contentions, notably personalized medicine’s ability to increase health care quality while lowering overall systemic costs. But this is the opportunity that our generation has been given. To make it a reality is going to require the combined resources of multiple stakeholders—all willing to invest in a paradigm change that can preserve innovation, improve outcomes, and reduce the overall costs of health care.

BOARD OF DIRECTORS

Chair
D. Stafford O’Kelly, retired
Abbott Molecular Inc.

Treasurer
David King
Laboratory Corporation of America (LabCorp)

Secretary
Jeffrey Cusman, M.D.
United States Diagnostic Standards (USDS)

Past President & Chair
J. Brian Munroe
Endo Pharmaceuticals

Past Chair
Wayne A. Rosenkranz, Jr., Ph.D., retired
Massachusetts Institute of Technology

Amy P. Abernethy, M.D.
Duke University

Joanne Armstrong, M.D., M.P.H
Aetna

Paul R. Billings, M.D., Ph.D.
Life Technologies

Donna Cryer, J.D.
American Liver Foundation

William S. Dalton, Ph.D., M.D.
Moffitt Cancer Center

Neil de Crescenzo
Oracle Corporation

Stephen L. Eck, M.D., Ph.D.
Astellas Pharma Global Development

Felix W. Frueh, Ph.D.
Third Rock Ventures

Timothy Garnett, MBBS, FRCOG
Eli Lilly and Company

Julie K. Goonewardene
American Medical Association

Lawrence J. Lesko, Ph.D., F.C.P.
University of Florida

Clay B. Marsh, M.D.
The Ohio State University

Aidan Power,
MB Bch MSc MRCPsych
Pfizer Inc

Lori M. Reilly, Esq.
PhRMA

Jared Schwartz, M.D., Ph.D.
Aperio

Nancy Simonian, M.D.
Syros Pharmaceuticals, Inc.

Dietrich Stephan, Ph.D.
Silicon Valley Biosystems

Michael Vasconcelles, M.D.
Millennium: The Takeda Oncology Company

STAFF

Edward Abrahams, Ph.D.
President

Mary Bordoni
Director of Membership & Development

Tiffany Harrington
Director of Public Affairs

Amy Miller, Ph.D.
Vice President, Public Policy

Fawwilla Sampson
Office Manager and Secretary to the Board

Timothy Swope
Policy & Communications Analyst
MEMBER LIST

CLINICAL LABORATORY TESTING SERVICES
3G Biotech (China) Company
Genelex Corporation
Iversen Genetic Diagnostics, Inc.
Laboratory Corporation of America (LabCorp)
Quest Diagnostics

DIAGNOSTIC COMPANIES
Abbott
Agenda BV
Alacris Theranostics GmbH
Allegro Diagnostics
Alimus Diagnostics
AltheaDX
Aperio
AssureRx Health, Inc.
ASURAGEN, Inc.
BD (Becton Dickinson & Co.)
Biodesix
BioMarker Strategies
Brain Resource Company Limited
Caprion Proteomics
CardioDx, Inc.
Caris Life Sciences
Crescendo Bioscience, Inc.
Curetis AG
Cylex Inc.
DiagCor Bioscience Incorporation Limited
Enterome
EuroLab
Expression Analysis, Inc.
Foundation Medicine, Inc.
Genomic Health, Inc.
IGNYTA, Inc.
Integrated Diagnostics
Interleukin Genetics, Inc.
InvitroScript Technologies
Luminex Corporation
Miraca Life Sciences
MolecularMD
Nodality
On-Q-ity
Predictive BIOSCIENCES, Inc.
Primer Dx
QIAGEN, Inc.
RIKEN GENESIS
Siemens Medical Solutions
Silicon Valley Biosystems
Strand Scientific Intelligence, Inc.
SunExam
TcLand Expression
Telome Health, Inc., (THI)
Tethys Bioscience
Verinata Health, Inc.
VitaPath Genetics, Inc.
XDi, Inc.

EMERGING BIOTECH/PHARMACEUTICAL COMPANIES
Alper Biotech, LLC
Cabernet Pharmaceuticals, Inc.
Debiopharm Group™

Genomind, LLC
Kinemed, Inc.
Onyx Pharmaceuticals
Paralab, LLC
Precision Biologics, Inc.
Selventa

HEALTH INSURANCE COMPANIES
Aetna
CVS Caremark

INDUSTRY & TRADE ASSOCIATIONS
AdvaMed (Advanced Medical Technology Association)
American Clinical Laboratory Association
BIO (Biotechnology Industry Organization)
PhRMA

IT/INFORMATICS COMPANIES
5AM Solutions, Inc.
Cytolon AG
GenomeQuest, Inc.
IDBS
McKesson
MolecularHealth
Oracle Health Sciences
PanGenX, Inc.
UNIConnect, LC
XIFIN, Inc.

LARGE BIOTECH/PHARMACEUTICAL COMPANIES
Amgen, Inc.
Astellas Pharma Global Development
Boehringer-Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
El Lilly and Company
EMD Serono
Endo Health Solutions
GE Healthcare
GlaxoSmithKline, PLC
Johnson & Johnson
Merck
Millennium: The Takeda Oncology Company
Novartis
Pfizer Inc.

PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple Sclerosis
Adrians Jenkins Foundation for Personalized Medicine
Alliance for Aging Research
American Liver Foundation
Tumour Society—Canada
Genomix Canada
Go Health America
International Cancer Advocacy Network (ICAN)
Melanoma Research Alliance Foundation (MRA)
Multiple Myeloma Research Foundation
PMC CONTINUED TO HAVE A VERY STRONG financial position in 2011. Revenues increased by 5 percent as a result of an expanded membership database. As a result, PMC ended the year with $321,000 of net surplus, which increased its reserves to nine months of expenditures compared to six months in 2010 (average in the industry for an organization of this size is six months). Net assets ratio remained strong as well at a healthy 78% compared to 72% in 2010 (average for similar nonprofits is 60%).

The financial results are derived from the PMC’s audited December 31, 2011 financial statements, which contain an unqualified audit opinion. PMC’s complete audited financial statements can be obtained at pmc@personalizedmedicinecoalition.org or by calling 202.589.1770.

### STATEMENT OF ACTIVITIES

<table>
<thead>
<tr>
<th>REVENUES</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership dues</td>
<td>$1,307,670</td>
</tr>
<tr>
<td>Sponsorship</td>
<td>204,500</td>
</tr>
<tr>
<td>Support for PMC Policy</td>
<td>20,000</td>
</tr>
<tr>
<td>Membership events</td>
<td>45,000</td>
</tr>
<tr>
<td>Admission fees</td>
<td>26,389</td>
</tr>
<tr>
<td>Interest income</td>
<td>1,440</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>6,433</td>
</tr>
<tr>
<td><strong>TOTAL REVENUES</strong></td>
<td><strong>$1,611,432</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENDITURES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>General &amp; administrative</td>
<td>944,601</td>
</tr>
<tr>
<td>Professional fees</td>
<td>142,391</td>
</tr>
<tr>
<td>Education</td>
<td>102,764</td>
</tr>
<tr>
<td>Business development</td>
<td>100,033</td>
</tr>
<tr>
<td><strong>TOTAL EXPENDITURES</strong></td>
<td><strong>$1,289,789</strong></td>
</tr>
</tbody>
</table>

| CHANGE IN NET ASSETS             | $ 321,643 |

### STATEMENT OF FINANCIAL POSITION

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>$1,165,075</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>19,383</td>
</tr>
<tr>
<td>Prepays, deposits, &amp; other assets</td>
<td>72,526</td>
</tr>
<tr>
<td>Property &amp; equipment, net</td>
<td>6,263</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$1,263,247</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable &amp; accrued expenses</td>
<td>19,604</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>252,250</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td><strong>$ 271,854</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted net assets</td>
<td>991,393</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td><strong>$ 991,393</strong></td>
</tr>
</tbody>
</table>

### 2011 REVENUES

<table>
<thead>
<tr>
<th></th>
<th>% TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership dues</td>
<td>81.15%</td>
</tr>
<tr>
<td>Sponsorship &amp; support</td>
<td>13.93%</td>
</tr>
<tr>
<td>Events &amp; fees</td>
<td>4.43%</td>
</tr>
<tr>
<td>Interest &amp; miscellaneous</td>
<td>0.49%</td>
</tr>
</tbody>
</table>
MISSION

The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. The Coalition’s mission is to educate policymakers and the public about the power and potential of individualized health care and raise the profile of personalized medicine so that both patients and the health system will benefit from improved clinical care and increased overall value.